Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 niraparib + abiraterone acetate + prednisone versus abiraterone acetate + prednisone in HRR-mutated metastatic castration-sensitive prostate cancer
NL-OMON59472Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of niraparib in prostate cancer (PCa) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Radiographic progression-free survival. Started Mar 2021; status: active, not recruiting.
02
Drugs
niraparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON59472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59472.